+1 (202) 780-3397THE HEPATOPROTECTIVE EFFECT’S RESULT OF NEW DRUG LONAL IN PATIENT WITH NON-ALCOHOLIC FATTY LIVER DISEASE CONCOMITANT WITH CHRONIC HEPATITIS
Joint Event on 4th International Conference on GASTROENTEROLOGY AND HEPATOLOGY & 9th World Congress on CLINICAL PHARMACY & PHARMACY PRACTICE
March 25-26, 2019 | Amsterdam, Netherlands
B Altanshagai, Z Ariunaa, Ts Sarnai and B Myagmarnaran
Treatment, Research and Production Company of The Mong-Em, Mongolia Mongolian National University of Medicinal Sciences, Mongolia New Medicine Medical University of Mongolia, Mongolia Mongolian University of Pharmaceutical Science, Mongolia
Scientific Tracks Abstracts : Arch Gen Intern Med
Abstract:
Introduction: Following researchers determined the Chronic hepatitis C virus infection which was 8,2% (Davaalkham.J
et al, 2003), 9,6% (Takahashi.M et al, 2004), 9,8% (Tsatsralt-Od.B et al, 2006), 11,8% (Dagvadorj.Ya et al 2005) in Mongolia.
As researchers noted that hepatitis C genotype 1 and 3 enable to be triglyceride accumulation for liver because it often
occurs simultaneously fatty liver disease. Although many types of traditional medicine have been used for for hundreds
years, their effectiveness of the therapy is relatively small with inadequate use of poorly understood in practice. These
types of medicine’s storage, form, flavor are to improve which are prepared based on scientific studying, is to make the
clinical trial of drug acts as easily use, emerged as one of the need for market. Therefore, our research team has made the
clinical trial based on the chemical and pharmacological study of hepatoprotective effect for lonicera Altaica Pall fruit, an
established clinical study and producing new drugs.
Material and Method: The research was considered such as clinical trial guideline for new drug issued by the WHO’s
“Good Clinical Practice”. Based on permission given by Biomedical Ethical Community of the Health Ministry of Mongolia
approved diagnosis patient with fatty liver disease associated with chronic hepatitis C. Research design is randomized
placebo-controlled, double blind clinical trial. We studied 3 groups of participants that was given the following treatment
for 21 days: (I) Treatment group: Lonal drug 1.4 gr ×3 times, (II) Control group: Silymarin drug 67.5 mg ×3 times, (III)
Placebo group: Placebo drug 1.4 gr ×3 times. We used on histo-morphometric analysis of liver biopsy DISKUS ver 4.80,
Olympus BX microscopy.
Results: Lonal drug decreases activation of syndrome hepatic cell cytolysis ALT (p=0.023), AST (p=0.037). Also decreases
criteria of cholestasic syndrome such as indirect bilirubin (p=0.611), ALP (p=0.04), GGT (p=0.445). The lonal medicine was
taken during 21 days and comparing the results of lipid metabolism exchange before and after treatment, reduces TG
(p=0,402), increases HDL (p=0.047). The participants have taken the fibroscan analysis and liver biopsy. That was compared
to determine before and after treatment such as steatosis and fibrosis degree. Before treatment degree of steatosis
was S2: 278.4±75.3 dB/m and after treatment it was dropped from S1: 238.6±70.4 dB/m (p <0.05). And before treatment,
such as fibrosis degree F2-3: 8.84 ± 2.2 kPa, after treatment it was decreased in F1-2: 7.18 ± 3.87 (p<0.01). In liver histology,
comparing before and after treatment the results of liver cell inflammation-fibrosis area was reduced by 1,75 times and
decreases hepatic steatosis degree (strong fatty change was improved mild fatty change).
Conclusion: New lonal medicine is reducing activation syndrome hepatic cell cytolysis, cholestatic and some criteria of
the metabolic syndrome in patient with fatty liver disease associated with chronic hepatitis C. Also new lonal medicine
reduces the degree of liver steatosis and fibrosis by the analysis of fibroscan and liver biopsy.
Biography:
B Altanshagai is a doctor and researcher of science, technology & production at “Monchemo” Co.,Ltd, Mongolia. She has been working at Monchemo as a researcher since 2013 when she was a bachelor’s degree student of New Medicine Medical University of Mongolia. Since 2016, She has been working as a doctor and researcher in treatment in research and production company of “Mong-em”.
E-mail: Ltnshg0802@gmail.com
PDF HTML